Core Insights - Analysts project that Alignment Healthcare (ALHC) will report a quarterly loss of -$0.15 per share, marking a 6.3% increase year over year in losses [1] - Revenue is expected to reach $1 billion, reflecting a significant increase of 42.9% compared to the same quarter last year [1] Earnings Projections - The consensus EPS estimate has been revised upward by 16.7% in the past 30 days, indicating a reassessment of initial estimates by covering analysts [2] - Changes in earnings projections are crucial for predicting investor reactions, with empirical studies showing a strong correlation between earnings estimate trends and short-term stock price movements [3] Key Metrics - Analysts estimate 'Revenues- Other' to be $10.57 million, representing an 11.8% increase from the previous year [5] - 'Revenues- Earned premiums' are projected to reach $990.31 million, indicating a 43.2% increase from the prior-year quarter [5] - The consensus estimate for the 'Medical Benefit Ratio' is 89.1%, up from 87.5% in the same quarter last year [5] - 'Health Plan Membership - Ending' is expected to be 233,752, compared to 189,100 reported in the same quarter of the previous year [6] Stock Performance - Alignment Healthcare shares have decreased by 6.5% over the past month, contrasting with the Zacks S&P 500 composite's decline of 0.3% [6] - The company holds a Zacks Rank of 3 (Hold), suggesting it is expected to closely follow overall market performance in the near term [6]

Core Viewpoint - RadNet (RDNT) is expected to report quarterly earnings of $0.19 per share, reflecting a 13.6% decline year over year, while revenues are forecasted to increase by 8% to $515.37 million [1] Group 1: Earnings and Revenue Estimates - The consensus EPS estimate has remained unchanged over the last 30 days, indicating analysts have reevaluated their initial estimates [1] - Analysts predict 'Revenue- Imaging Center' will reach $488.78 million, representing a year-over-year increase of 4.8% [4] - 'Revenue- Revenue under capitation arrangements' is estimated at $30.73 million, indicating a decline of 2.5% from the prior-year quarter [4] Group 2: Service Fees and Digital Health Revenue - The 'Revenue- Service fee' is expected to be $484.98 million, showing an increase of 8.8% from the previous year [5] - The consensus estimate for 'Revenue- Digital Health' stands at $22.52 million, reflecting a significant increase of 19.2% year over year [5] Group 3: Stock Performance and Analyst Ratings - Over the past month, shares of RadNet have decreased by 6.5%, compared to a decline of 0.3% in the Zacks S&P 500 composite [5] - RadNet currently holds a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [5]

Core Viewpoint - Analysts forecast Jazz Pharmaceuticals (JAZZ) to report quarterly earnings of $6.62 per share, reflecting a year-over-year increase of 0.3%, with anticipated revenues of $1.18 billion, an increase of 8.4% compared to the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised downward by 13% in the past 30 days, indicating a reassessment by covering analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock performance [3]. Revenue Projections - Analysts project 'Total revenues- Oncology- Vyxeos' to be $47.69 million, a decrease of 10.4% year-over-year [5]. - For 'Total revenues- Oncology- Defitelio/defibrotide', the estimate is $56.26 million, reflecting a decline of 2.4% [5]. - 'Total revenues- Neuroscience- Oxybate- Xywav' is expected to reach $448.99 million, an increase of 12% from the previous year [6]. - 'Total revenues- Neuroscience- Epidiolex/Epidyolex' is projected at $297.23 million, showing an 8.1% increase [6]. - The consensus for 'Total revenues- Neuroscience- Total' is $783.39 million, indicating a year-over-year change of 7.2% [7]. - 'Total revenues- Oncology- Total' is estimated at $322.89 million, reflecting a 10.7% increase [8]. - 'Total revenues- Oncology- Rylaze/Enrylaze' is projected at $105.81 million, suggesting a 4.3% year-over-year change [8]. - 'Total revenues- Oncology- Zepzelca' is expected to be $84.24 million, indicating a 7.6% increase [9]. - 'Revenues- Product sales, net' is anticipated to be $1.11 billion, reflecting an 8.2% increase [9]. - 'Revenues- Royalties and contract revenues' is projected at $63.75 million, indicating a 1.3% increase [9]. Stock Performance - Over the past month, Jazz shares have recorded a return of -0.3%, compared to the Zacks S&P 500 composite's -0.8% change [10]. - Based on its Zacks Rank 3 (Hold), JAZZ is expected to perform in line with the overall market in the upcoming period [10].

Core Viewpoint - Analysts expect FMC Technologies (FTI) to report quarterly earnings of $0.51 per share, reflecting a year-over-year decline of 5.6%, while revenues are projected to be $2.55 billion, an increase of 7.6% from the previous year [1] Earnings Estimates - The consensus EPS estimate has been revised 0.4% higher in the last 30 days, indicating a collective reevaluation by analysts [1][2] Revenue Projections - Revenue from Subsea Technologies is expected to reach $2.23 billion, marking an 8.7% increase year-over-year [4] - Revenue from Surface Technologies is projected at $322 million, reflecting a 0.8% increase from the prior year [4] - Revenue from Lease is estimated at $71.31 million, indicating a significant increase of 24% year-over-year [4] - Revenue from Product is anticipated to be $922.80 million, showing an 8.3% increase from the previous year [5] Geographic Revenue Estimates - Revenue from Surface Technologies in Europe and Central Asia is expected to be $33.62 million, a 13.2% increase year-over-year [5] - Revenue from Surface Technologies in Africa is projected at $15.95 million, reflecting a 24.6% increase [6] - Revenue from Surface Technologies in North America is estimated at $105.63 million, indicating a decline of 1.6% from the prior year [6] - Revenue from Surface Technologies in the Middle East is expected to be $118.75 million, reflecting a decrease of 5% year-over-year [7] Order Backlog and Inbound Orders - The Order Backlog for Subsea Technologies is estimated at $16.31 billion, up from $13.52 billion year-over-year [8] - The total Order Backlog is projected to reach $17.06 billion, compared to $14.38 billion a year ago [8] - The Order Backlog for Surface Technologies is expected to be $728.81 million, down from $858.20 million year-over-year [8] - Inbound Orders for Subsea Technologies are forecasted to be $2.45 billion, down from $2.70 billion in the same quarter last year [7] Stock Performance - FMC Technologies shares have shown a return of +17.4% over the past month, outperforming the Zacks S&P 500 composite, which declined by -1.3% [10]

Core Viewpoint - Skyward Specialty Insurance (SKWD) is expected to report a quarterly earnings per share (EPS) of $0.93, reflecting a 16.3% increase year-over-year, with revenues projected at $374 million, a 22.9% increase compared to the previous year [1]. Earnings Projections - The consensus EPS estimate has been revised downward by 2.9% in the last 30 days, indicating a reassessment by analysts [2]. - Changes in earnings projections are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate trends and short-term stock price movements [3]. Revenue Estimates - Analysts project 'Revenues- Net investment income' to be $22.96 million, representing a 10.8% increase from the prior-year quarter [4]. - 'Revenues- Net earned premiums' are expected to reach $349.51 million, indicating a 19.2% year-over-year change [5]. Key Metrics - The estimated 'Expense ratio' is 28.5%, down from 28.9% in the same quarter last year [5]. - The consensus estimate for the 'Loss ratio' is 62.6%, a decrease from 66.9% a year ago [5]. - Analysts expect the 'Combined ratio' to be 91.1%, compared to 95.8% in the previous year [6]. Stock Performance - Skyward shares have increased by 1.7% over the past month, contrasting with a -1.3% change in the Zacks S&P 500 composite [6]. - The company holds a Zacks Rank of 3 (Hold), suggesting it is expected to closely follow overall market performance in the near term [6].

Core Viewpoint - Analysts project that Advanced Drainage Systems (WMS) will report quarterly earnings of $1.11 per share, reflecting a year-over-year increase of 1.8%, while revenues are expected to decline by 0.6% to $686.55 million [1] Earnings Projections - The consensus EPS estimate for the quarter has been revised upward by 0.7% over the past 30 days, indicating a collective reassessment by analysts [2] - Changes in earnings projections are crucial for predicting investor reactions, with empirical studies showing a strong correlation between earnings estimate trends and short-term stock price movements [3] Key Metrics Forecast - Analysts estimate 'Adjusted Gross Profit- Pipe' at $96.85 million, up from $90.90 million in the same quarter last year [5] - The forecast for 'Adjusted Gross Profit- International' is $11.40 million, down from $12.07 million year-over-year [5] - 'Adjusted Gross Profit- Allied Products & Other' is expected to be $94.15 million, compared to $92.94 million in the previous year [6] - 'Adjusted Gross Profit- Infiltrator' is projected at $80.65 million, an increase from $78.29 million in the same quarter last year [6] Stock Performance - Shares of Advanced Drainage have returned +4.6% over the past month, outperforming the Zacks S&P 500 composite, which saw a +0.9% change [6] - With a Zacks Rank 3 (Hold), WMS is anticipated to reflect overall market performance in the near future [6]

Core Viewpoint - Analysts forecast that Boston Scientific (BSX) will report quarterly earnings of $0.78 per share, reflecting an 11.4% year-over-year increase, with revenues expected to reach $5.27 billion, a 15.4% increase compared to the previous year [1]. Earnings Estimates - Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter, indicating stability in analysts' forecasts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong relationship between earnings estimate revisions and short-term stock performance [3]. Revenue Projections - Analysts predict 'Net Sales- MedSurg- Worldwide' will reach $1.80 billion, indicating an 11.5% year-over-year change [5]. - The consensus estimate for 'Net Sales- Cardiovascular- Worldwide' stands at $3.46 billion, reflecting a 17.5% increase from the year-ago quarter [5]. - 'Net Sales- MedSurg- Urology- Worldwide' is expected to be $725.74 million, showing a 15.2% year-over-year change [5]. - 'Net Sales- MedSurg- Endoscopy- Worldwide' is forecasted to reach $756.05 million, indicating a 9.6% increase from the previous year [6]. - 'Geographic Revenue- Rest of the World' is projected to be $1.88 billion, reflecting a 12.4% year-over-year change [6]. - 'Geographic Revenue- U.S.' is expected to reach $3.39 billion, indicating a 17% increase [6]. - 'Net Sales- Cardiovascular- Peripheral Interventions- International' is estimated at $297.57 million, suggesting an 11% year-over-year change [7]. - 'Net Sales- MedSurg- Neuromodulation- United States' is projected to be $247.55 million, reflecting a 7.2% increase [7]. - 'Net Sales- MedSurg- Neuromodulation- International' is expected to be $75.13 million, indicating a 10.5% year-over-year change [8]. - 'Net Sales- MedSurg- Endoscopy- United States' is forecasted to reach $462.66 million, reflecting a 9.4% increase [8]. - 'Net Sales- MedSurg- Endoscopy- International' is projected at $293.49 million, indicating a 9.9% year-over-year change [9]. - 'Net Sales- MedSurg- Urology- United States' is expected to be $545.86 million, reflecting an 18.9% increase from the previous year [9]. Stock Performance - Over the past month, shares of Boston Scientific have returned -3.2%, while the Zacks S&P 500 composite has changed by +0.9% [9]. - Currently, BSX carries a Zacks Rank 2 (Buy), suggesting potential outperformance in the near future [9].

Core Viewpoint - Analysts expect SEI Investments (SEIC) to report quarterly earnings of $1.34 per share, reflecting a year-over-year increase of 12.6%, with revenues projected at $595.79 million, up 6.9% from the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised 0.9% higher over the last 30 days, indicating a collective reevaluation by analysts [1][2]. Revenue Projections - Revenue from Asset management, administration, and distribution fees is expected to be $472.28 million, a 7.5% increase year-over-year [4]. - Revenue from Information processing and software servicing fees is projected at $123.71 million, reflecting a 5.1% increase from the prior year [4]. - Revenue from Private Banks is anticipated to be $147.29 million, also a 5.1% increase from the previous year [5]. - Revenue from Investments in New Business is expected to decline to $9.59 million, a significant decrease of 38.9% year-over-year [5]. Assets Under Management - Assets under management for Investments in New Business are estimated at $3.16 billion, up from $3.04 billion year-over-year [5]. - Assets under management for Investment Advisors are projected to reach $97.05 billion, compared to $79.39 billion last year [6]. - Assets under management for Private Banks are expected to be $31.45 billion, an increase from $28.22 billion year-over-year [6]. - Institutional Investors' assets under management are forecasted to be $85.14 billion, up from $76.99 billion in the same quarter last year [7]. - Assets under management for LSV - Equity and Fixed Income programs are estimated at $82.09 billion, down from $86.50 billion year-over-year [7]. - Total assets under management for Investment Managers are projected to reach $240.47 billion, up from $202.57 billion last year [8]. Client Assets Under Administration - Client assets under administration for Investment Managers are expected to reach 1,223,549, compared to 1,032,812 in the previous year [8]. - Client assets under administration for Private Banks are projected to be 8,713, an increase from 8,340 year-over-year [9]. Stock Performance - Over the past month, SEI shares have returned +1.5%, outperforming the Zacks S&P 500 composite's +0.4% change, indicating a positive outlook for the stock [10].

Core Viewpoint - Analysts forecast that Visa will report quarterly earnings of $3.14 per share, reflecting a year-over-year increase of 14.2%, with revenues expected to reach $10.69 billion, an increase of 12.4% compared to the previous year [1] Earnings Estimates - Changes in earnings estimates are crucial for predicting investor reactions to stock performance, with empirical studies showing a strong relationship between earnings estimate revisions and short-term stock price performance [2] Key Metrics Projections - Analysts estimate 'Revenues- Service revenue' at $4.68 billion, indicating a year-over-year change of +11.2% [4] - The average prediction for 'Revenues- Data processing revenue' is $5.44 billion, reflecting a year-over-year change of +14.6% [4] - 'Revenues- Other revenue' is projected to be $1.09 billion, showing a change of +19.4% from the previous year [4] International and Total Payments Volume - 'Revenues- International transaction revenue' is expected to reach $3.85 billion, suggesting a year-over-year increase of +11.8% [5] - 'End of Period Connections - Total transactions' is projected to be 69.85 billion, up from 63.80 billion year-over-year [5] - 'Payments volume - Total' is forecasted to reach $3828.52 billion, compared to $3522.00 billion in the previous year [5] Regional Payments Volume - 'Payments volume - Canada' is estimated at $117.01 billion, up from $111.00 billion in the same quarter last year [6] - 'Payments volume - CEMEA' is projected at $244.88 billion, compared to $211.00 billion in the same quarter of the previous year [6] - 'Payments volume - LAC' is expected to reach $277.20 billion, compared to $242.00 billion year-over-year [7] - 'Payments volume - U.S.A' is estimated at $1834.14 billion, up from $1720.00 billion in the same quarter last year [8] - 'Payments volume - Europe' is projected to be $798.70 billion, compared to $714.00 billion in the previous year [8] Stock Performance - Visa shares have shown a return of -8.1% over the past month, while the Zacks S&P 500 composite has increased by +0.2%, with Visa expected to mirror the overall market performance in the near future [8]

Core Insights - Analysts project Corning (GLW) will report quarterly earnings of $0.70 per share, reflecting a 22.8% year-over-year increase, with revenues expected to reach $4.32 billion, an 11.6% increase from the same quarter last year [1] Earnings Estimates - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analysts' assessments [1][2] - Changes in earnings estimates are crucial for predicting investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock performance [2] Key Metrics Forecast - Analysts estimate 'Net Sales- Display Technologies' at $880.85 million, a decrease of 9.3% year over year [4] - 'Net Sales- Hemlock and Emerging Growth Businesses' is projected at $464.86 million, an increase of 24.6% year over year [4] - 'Net Sales- Specialty Materials' is expected to reach $587.56 million, indicating a 14.1% increase from the prior-year quarter [4] Segment Sales and Income - The consensus for 'Net Sales- Life Sciences' is $249.13 million, showing a slight decline of 0.4% year over year [5] - 'Net Sales- Optical Communications' is forecasted at $1.71 billion, reflecting a 24.8% increase from the year-ago quarter [5] - 'Segment Net Income- Display Technologies' is expected to be $216.95 million, down from $262.00 million in the same quarter last year [5][6] - 'Segment Net Income- Life Sciences' is projected at $17.35 million, compared to $18.00 million a year ago [6] - 'Segment Net Income- Optical Communications' is anticipated to reach $261.29 million, up from $194.00 million last year [6] - 'Segment Net Income- Specialty Materials' is estimated at $98.80 million, compared to $81.00 million in the previous year [7] Stock Performance - Over the past month, Corning's shares have returned +5.2%, outperforming the Zacks S&P 500 composite's +0.6% change [7] - Corning currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance in the near future [7]